Reply to Ensina et al
2018; Wiley; Volume: 29; Issue: 6 Linguagem: Inglês
10.1111/pai.12963
ISSN1399-3038
AutoresMaria‐Magdalena Balp, Karsten Weller, V. Carboni, Alexandra Chirilov, C. Papavassilis, Thomas Severin, Haijun Tian, Torsten Zuberbier, Marcus Maurer,
Tópico(s)Drug-Induced Adverse Reactions
ResumoPediatric Allergy and ImmunologyVolume 29, Issue 6 p. 670-671 CORRESPONDENCE Reply to Ensina et al Maria-Magdalena Balp, Corresponding Author Maria-Magdalena Balp maria-magdalena.balp@novartis.com orcid.org/0000-0002-8612-7680 Novartis Pharma AG, Basel, SwitzerlandCorrespondence: Maria-Magdalena Balp, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland (maria-magdalena.balp@novartis.com).Search for more papers by this authorKarsten Weller, Karsten Weller Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this authorVeruska Carboni, Veruska Carboni GfK Switzerland AG, Risch-Rotkreuz, SwitzerlandSearch for more papers by this authorAlexandra Chirilov, Alexandra Chirilov GfK SE, Nuremberg, GermanySearch for more papers by this authorCharis Papavassilis, Charis Papavassilis Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorThomas Severin, Thomas Severin Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorHaijun Tian, Haijun Tian Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorTorsten Zuberbier, Torsten Zuberbier Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this authorMarcus Maurer, Marcus Maurer Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this author Maria-Magdalena Balp, Corresponding Author Maria-Magdalena Balp maria-magdalena.balp@novartis.com orcid.org/0000-0002-8612-7680 Novartis Pharma AG, Basel, SwitzerlandCorrespondence: Maria-Magdalena Balp, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland (maria-magdalena.balp@novartis.com).Search for more papers by this authorKarsten Weller, Karsten Weller Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this authorVeruska Carboni, Veruska Carboni GfK Switzerland AG, Risch-Rotkreuz, SwitzerlandSearch for more papers by this authorAlexandra Chirilov, Alexandra Chirilov GfK SE, Nuremberg, GermanySearch for more papers by this authorCharis Papavassilis, Charis Papavassilis Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorThomas Severin, Thomas Severin Novartis Pharma AG, Basel, SwitzerlandSearch for more papers by this authorHaijun Tian, Haijun Tian Novartis Pharmaceuticals Corporation, East Hanover, New JerseySearch for more papers by this authorTorsten Zuberbier, Torsten Zuberbier Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this authorMarcus Maurer, Marcus Maurer Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for more papers by this author First published: 27 July 2018 https://doi.org/10.1111/pai.12963Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume29, Issue6September 2018Pages 670-671 RelatedInformation
Referência(s)